Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 3

Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin

Authors Serkan Öncü

Published 15 July 2007 Volume 2007:3(3) Pages 441—448

Serkan Öncü

Adnan Menderes University Medical Faculty, Department of Infectious Diseases and Clinical Microbiology, Aydin, Turkey

Abstract: Community-acquired pneumonia (CAP) is the cause of substantial morbidity, mortality, and resource utilization worldwide. When choosing an antimicrobial, effective treatment depends on proper patient evaluation and the identification of numerous risk factors, such as recent antibiotic exposure or the presence of comorbidity. Patients without any risk factor should be treated effectively with a narrow spectrum β-lactam agent, like amoxicillin, or a macrolide. If a risk factor is present, agents with a broader spectrum of activity should be selected for the empirical therapy. The newer-generation quinolones are suitable agents with their excellent in vitro activity and pharmacodynamic–pharmacokinetic properties. They are not only active against susceptible CAP pathogens, but also against the resistant strains. Among the quinolones, gemifloxacin has the best in vitro activity. Its improved bioavailability, pharmacokinetic–pharmacodynamic properties, and safety profile make this agent an excellent option for the treatment of CAP.

Keywords: treatment, community-acquired pneumonia, gemifloxacin

Download Article [PDF] 

Readers of this article also read:

Liver-targeted cyclosporine A-encapsulated poly (lactic-co-glycolic) acid nanoparticles inhibit hepatitis C virus replication

Jyothi KR, Beloor J, Jo A, Nguyen MN, Choi TG, Kim JH, Akter S, Lee SK, Maeng CH, Baik HH, Kang I, Ha J, Kim SS

International Journal of Nanomedicine 2015, 10:903-921

Published Date: 30 January 2015

Surface modifications of silica nanoparticles are crucial for their inert versus proinflammatory and immunomodulatory properties

Marzaioli V, Aguilar-Pimentel JA, Weichenmeier I, Luxenhofer G, Wiemann M, Landsiedel R, Wohlleben W, Eiden S, Mempel M, Behrendt H, Schmidt-Weber C, Gutermuth J, Alessandrini F

International Journal of Nanomedicine 2014, 9:2815-2832

Published Date: 5 June 2014

Causal diagrams and the logic of matched case-control studies

Shahar E, Shahar DJ

Clinical Epidemiology 2012, 4:137-144

Published Date: 15 May 2012

Did depressive symptoms affect recognition of emotional prosody in Parkinson’s disease?

Adriana Vélez Feijó, Carlos RM Rieder, Márcia LF Chaves

Neuropsychiatric Disease and Treatment 2008, 4:669-674

Published Date: 6 June 2008

A review of ramelteon in the treatment of sleep disorders

David N Neubauer

Neuropsychiatric Disease and Treatment 2008, 4:69-79

Published Date: 8 February 2008

Sleep disturbances and suicide risk: A review of the literature

Rebecca A Bernert, Thomas E Joiner

Neuropsychiatric Disease and Treatment 2007, 3:735-743

Published Date: 15 January 2008

Treatment of premenstrual dysphoric disorder (PMDD) with a novel formulation of drospirenone and ethinyl estradiol

Domenico De Berardis, Nicola Serroni, Rosa Maria Salerno, Filippo Maria Ferro

Therapeutics and Clinical Risk Management 2007, 3:585-590

Published Date: 15 September 2007

Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B

Eugene B Kern, David Sherris, Angelos M Stergiou, Laura M Katz, Lisa C Rosenblatt, Jens Ponikau

Therapeutics and Clinical Risk Management 2007, 3:319-325

Published Date: 15 May 2007